A better understanding of the role of PARPs and PARylation during viral infection is fundamental; while several FDA-approved PARP inhibitors exist and are used as targeted cancer drugs, their potential efficacy in treating viral infection and wider viral-associated pathogenesis has not been tested yet. The gene discussed is PARP1; the disease is cancer.